Abstract:
The WHO advocates introduction of routine HPV vaccination as part of a national EPI programme provided HPV prevention is considered a health priority, and the programme is logistically feasible and financially sustainable. High vaccine costs are often cited as barriers to national public health usage. However, a recent study in Cape Town showed a cost benefit for routine HPV vaccination use. Cervical cancer screening programmes should continue, as genotypes not included in the vaccines may still cause malignant transformation.
